Eli Lilly and Company (NYSE:LLY) Earns “Outperform” Rating from Royal Bank Of Canada

Posted by Geri Gentry on Oct 14th, 2026

Eli Lilly and Company logo Eli Lilly and Company (NYSE:LLY – Get Free Report)‘s stock had its “outperform” rating reissued by research analysts at Royal Bank Of Canada in a report issued on Monday, MarketBeat reports. They presently have a $1,500.00 price target on the stock. Royal Bank Of Canada’s price target indicates a potential upside of 28.53% from the stock’s current price.

Other equities research analysts have also issued reports about the stock. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an “overweight” rating in a research note on Monday, September 28th. Morgan Stanley boosted their target price on shares of Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Bank of America upped their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Finally, Berenberg Bank set a $1,400.00 price target on shares of Eli Lilly and Company and gave the stock a “buy” rating in a report on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,313.43.

Read Our Latest Research Report on LLY

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,167.01 on Monday. Eli Lilly and Company has a 12-month low of $783.85 and a 12-month high of $1,292.65. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The business’s 50-day moving average price is $1,176.60 and its two-hundred day moving average price is $1,102.08. The stock has a market cap of $1.10 trillion, a PE ratio of 37.56, a P/E/G ratio of 1.52 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business’s quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts expect that Eli Lilly and Company will post 34.79 earnings per share for the current fiscal year.

Insider Activity

In other news, CAO Donald Zakrowski sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock valued at $15,958,170 over the last quarter. 0.14% of the stock is owned by company insiders.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Signal Advisors Wealth LLC lifted its holdings in shares of Eli Lilly and Company by 13.6% during the third quarter. Signal Advisors Wealth LLC now owns 12,708 shares of the company’s stock worth $14,705,000 after purchasing an additional 1,517 shares during the period. Ifrah Financial Services Inc. grew its stake in shares of Eli Lilly and Company by 1.0% in the third quarter. Ifrah Financial Services Inc. now owns 2,735 shares of the company’s stock worth $3,165,000 after purchasing an additional 26 shares during the last quarter. Foster Group Inc. grew its stake in shares of Eli Lilly and Company by 2.5% in the third quarter. Foster Group Inc. now owns 2,190 shares of the company’s stock worth $2,534,000 after purchasing an additional 54 shares during the last quarter. Ulrich Consultants & Investment Group LLC acquired a new stake in Eli Lilly and Company in the third quarter valued at $380,000. Finally, Krilogy Financial LLC increased its holdings in Eli Lilly and Company by 1.0% in the third quarter. Krilogy Financial LLC now owns 6,914 shares of the company’s stock valued at $8,177,000 after purchasing an additional 68 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Erste Group raised its Eli Lilly earnings estimates to $36.55 per share for fiscal 2026 and $47.30 for 2027, modestly above its prior forecasts and the current consensus, signaling continued confidence in the company’s earnings momentum. Erste Group earnings estimates
Positive Sentiment: Analysts continue to highlight Lilly’s rapid revenue and profit growth, supported by strong demand for diabetes and weight-loss medicines. Recent commentary suggests the company could raise its revenue outlook, while RBC reiterated an “outperform” rating and a $1,500 price target. Lilly growth and analyst outlook
Positive Sentiment: Investors are focused on retatrutide, Lilly’s next-generation obesity candidate, which could potentially become a larger growth driver than Zepbound if clinical results support its efficacy and commercial viability. The company reports earnings on October 29, with updates on retatrutide likely to attract more attention than the quarterly results themselves. Retatrutide and upcoming earnings
Positive Sentiment: Lilly is collaborating with Prelude Therapeutics on a Phase 1 breast-cancer trial evaluating PRT13722 with Verzenio and Inluriyo. Enrollment is expected to begin in the fourth quarter of 2026, adding another potential pipeline opportunity, although the program remains early stage. Prelude collaboration
Neutral Sentiment: A Phase 3b study of Taltz combined with Zepbound showed improved skin clearance and weight loss in adults with plaque psoriasis and obesity, potentially supporting broader use of Lilly’s medicines, though the data are not yet a major revenue contributor. Taltz and Zepbound trial
Negative Sentiment: Shares have pulled back amid profit-taking after a major run-up and concerns that Lilly’s premium valuation leaves less room for execution mistakes. The stock trades near record levels at roughly 39 times earnings, making upcoming guidance and pipeline updates especially important. Lilly stock pullback
Negative Sentiment: A combination treatment produced more weight loss than Zepbound alone but also had substantially higher discontinuation rates, raising questions about tolerability and the eventual commercial potential of next-generation obesity therapies. Weight-loss combination study

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.